1. Home
  2. ETNB vs TEN Comparison

ETNB vs TEN Comparison

Compare ETNB & TEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • TEN
  • Stock Information
  • Founded
  • ETNB 2018
  • TEN 1993
  • Country
  • ETNB United States
  • TEN Greece
  • Employees
  • ETNB N/A
  • TEN N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • TEN
  • Sector
  • ETNB Health Care
  • TEN
  • Exchange
  • ETNB Nasdaq
  • TEN NYSE
  • Market Cap
  • ETNB 867.4M
  • TEN 772.2M
  • IPO Year
  • ETNB 2019
  • TEN N/A
  • Fundamental
  • Price
  • ETNB $7.93
  • TEN $20.24
  • Analyst Decision
  • ETNB Buy
  • TEN Hold
  • Analyst Count
  • ETNB 7
  • TEN 1
  • Target Price
  • ETNB $30.33
  • TEN $24.00
  • AVG Volume (30 Days)
  • ETNB 901.8K
  • TEN 385.6K
  • Earning Date
  • ETNB 11-07-2024
  • TEN 11-26-2024
  • Dividend Yield
  • ETNB N/A
  • TEN 8.90%
  • EPS Growth
  • ETNB N/A
  • TEN N/A
  • EPS
  • ETNB N/A
  • TEN 5.66
  • Revenue
  • ETNB N/A
  • TEN $822,543,000.00
  • Revenue This Year
  • ETNB N/A
  • TEN N/A
  • Revenue Next Year
  • ETNB $133.30
  • TEN $10.35
  • P/E Ratio
  • ETNB N/A
  • TEN $3.57
  • Revenue Growth
  • ETNB N/A
  • TEN N/A
  • 52 Week Low
  • ETNB $7.00
  • TEN $18.88
  • 52 Week High
  • ETNB $16.63
  • TEN $31.48
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 42.09
  • TEN 29.41
  • Support Level
  • ETNB $9.00
  • TEN $20.02
  • Resistance Level
  • ETNB $10.01
  • TEN $21.34
  • Average True Range (ATR)
  • ETNB 0.80
  • TEN 0.73
  • MACD
  • ETNB -0.10
  • TEN -0.05
  • Stochastic Oscillator
  • ETNB 8.52
  • TEN 8.06

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About TEN TSAKOS ENERGY NAVIGATION

Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.

Share on Social Networks: